Google updates site reputation abuse guidance on editorially overseen affiliate content

Google has updated its site reputation abuse guidance, often called the "parasite SEO" policy, to spell out when it is unlikely to take enforcement action against affiliate content on a publisher's website ^[1]. The update, detailed in an official Google blog post and revised documentation, says Google generally will not act against affiliate content written by a freelancer if the publisher shows editorial oversight and the material is created specifically for that publication ^[1].

The policy change also splits enforcement by region. Starting August 30, manual actions for site reputation abuse will affect search results shown to users outside the European Economic Area (EEA), but for users inside the EEA, the affected section of a site will instead be separated in Google's systems so it can rank on its own, without a manual-action penalty ^[1]. Google says this shift followed discussions with the European Commission ^[1].

Google laid out four factors it weighs when reviewing a site for this kind of abuse: how consistent the content's design and formatting are with the rest of the site, whether the content's quality matches the main site, whether authorship is clearly stated or disputed, and whether the same or nearly identical content appears on other sites ^[1]. Google says these are not a strict checklist but are considered together to judge whether a third party is exploiting a site's ranking power ^[1].

To illustrate, Google described a scenario it considers low-risk: a news site adds a cooking section written by a freelancer who also writes for other outlets, but the publisher identifies the freelancer, takes editorial responsibility, matches its own branding and formatting, and clearly discloses affiliate links, with content tailored to that publication rather than duplicated elsewhere ^[1]. By contrast, Google described a business publication hosting an unauthored article linking to a CBD marketplace, with no identified editor, no disclosure of commercial content, no place in the site's navigation, and text duplicated from a third-party marketplace, as an example likely to draw enforcement outside the EEA ^[1].

Why it matters for patients

Many people research GLP-1 medications such as semaglutide (Ozempic, Wegovy, Rybelsus), tirzepatide (Mounjaro, Zepbound), and orforglipron (Foundayo) on health websites that include affiliate links to pharmacies, coupon programs, or telehealth services. This guidance does not change medical information itself, but it signals what Google looks for when deciding whether such content stays visible in search results ^[1]. Sites that clearly name their writers, disclose commercial relationships, and integrate content into their normal editorial structure are less likely to be penalized, according to the update ^[1]. Sites that publish unattributed, duplicated, or undisclosed affiliate material are more likely to face reduced visibility outside the EEA ^[1]. For readers, this could mean that health information appearing in search results is somewhat more likely to come from sites showing visible editorial accountability, though Google's guidance does not guarantee accuracy of medical content and is not itself a quality certification.

What happens next

Google says manual actions under the updated policy begin affecting non-EEA search results on August 30 ^[1]. Inside the EEA, previously applied manual actions under this policy will be removed, and affected sections of sites will instead be categorized separately in Google's ranking systems rather than penalized ^[1]. Google says site owners will continue to be notified through Search Console and can file reconsideration requests, and that eligible EEA sites can also pursue mediation after a reconsideration request ^[1]. It is not yet known how quickly these changes will visibly affect search rankings for individual health or GLP-1-focused websites.